Hille Vax, Inc. HLVX
We take great care to ensure that the data presented and summarized in this overview for HilleVax, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HLVX
View all-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$19.2 Million1.01% of portfolio
-
Tang Capital Management LLC San Diego, CA4.92MShares$8.91 Million0.74% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$3.78 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.96MShares$3.54 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.88MShares$3.41 Million0.06% of portfolio
-
Carlyle Group Inc. Washington, DC1.84MShares$3.33 Million0.49% of portfolio
-
Abingworth LLP London, X01.84MShares$3.33 Million10.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.57MShares$2.85 Million0.0% of portfolio
-
Braidwell LP Stamford, CT1.06MShares$1.93 Million0.05% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.01MShares$1.84 Million0.0% of portfolio
Latest Institutional Activity in HLVX
Top Purchases
Top Sells
About HLVX
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Insider Transactions at HLVX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 22
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.78%
|
$84,000
$14.73 P/Share
|
May 21
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.77%
|
$84,000
$14.21 P/Share
|
May 20
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.77%
|
$90,000
$15.45 P/Share
|
May 03
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
723
-0.09%
|
$10,122
$14.15 P/Share
|
May 02
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.76%
|
$84,000
$14.01 P/Share
|
May 01
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
175
-0.02%
|
$2,450
$14.03 P/Share
|
Apr 05
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.75%
|
$84,000
$14.44 P/Share
|
Apr 04
2024
|
Frazier Life Sciences X, L.P. |
BUY
Open market or private purchase
|
Direct |
8,850
+0.1%
|
$123,900
$14.5 P/Share
|
Apr 04
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.75%
|
$84,000
$14.71 P/Share
|
Apr 03
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.74%
|
$84,000
$14.93 P/Share
|
Mar 28
2024
|
Sean Mc Loughlin Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
1,250
+50.0%
|
$20,000
$16.98 P/Share
|
Mar 20
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.74%
|
$985,326,000
$164221.0 P/Share
|
Mar 19
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.73%
|
$102,000
$17.42 P/Share
|
Mar 18
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.73%
|
$102,000
$17.66 P/Share
|
Mar 08
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.72%
|
$108,000
$18.66 P/Share
|
Mar 07
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.72%
|
$108,000
$18.37 P/Share
|
Mar 06
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.71%
|
$108,000
$18.95 P/Share
|
Feb 22
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.71%
|
$90,000
$15.05 P/Share
|
Feb 21
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.7%
|
$84,000
$14.92 P/Share
|
Feb 20
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.7%
|
$84,000
$14.88 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 330K shares |
---|---|
Open market or private purchase | 10.1K shares |
Open market or private sale | 171K shares |
---|